TQ-B3234 for adults with non-surgical neurofibromatosis type 1 tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an oral capsule called TQ-B3234 for adults who have painful, inoperable nerve tumors from neurofibromatosis type 1. It aims to see if the drug can shrink these tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with neurofibromatosis type 1 (NF1).
- You have at least one nerve tumor (plexiform neurofibroma) that is at least 3 cm in size and cannot be removed with surgery.
- Your doctor agrees you need treatment for symptoms from the tumor.
- You have not changed your nerve pain medications in the last 28 days.
- You are well enough to perform daily activities (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests an oral medication called PAS-004 for adults with Neurofibromatosis Type 1 who have at least one symptomatic plexiform neurofibroma that cannot be surgically removed. The goal is to see if the drug can shrink these tumors or improve symptoms, and to understand side effects.
Hear when a new Plexiform Neurofibroma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.